Amgen Inc. AMGN NASDAQ

Amgen Inc. (AMGN) generated $9.96B in operating cash flow for fiscal year 2025. After capital expenditures of $1.86B, free cash flow was $8.1B.

Free cash flow margin was 22% of revenue. Cash conversion ratio was 1.29x, indicating earnings are backed by cash.

The company returned $5.12B in dividends to shareholders during the period.

Criteria supported by this page:

• HEALTH (33/100, Fail) — weak cash flow raises concerns about debt servicing
• MOAT (81/100, Pass) — $8.1B (22% FCF margin) supports a durable competitive advantage
• INCOME (85/100) — Cash conversion ratio was 1.29x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 64/100 with 4/7 criteria passed.